Farmington, CT, June 29, 2022 – Oscillo Biosciences received a Phase I Small Business Innovation Research (SBIR) Award from the National Institutes of Health— National Institute on Aging. The $449,695 grant will support research on the usability and feasibility of the biotech company’s SynchronyGamma device as a music-based intervention for Alzheimer’s Disease and mild cognitive impairment (MCI).
The Oscillo Biosciences mission is to awaken hope for all people living with Alzheimer’s Disease and related disorders by developing effective, affordable, non-invasive, non- pharmacological treatments that combine the power of music with the latest breakthroughs in neuroscience to stimulate change in the brain.
Based on evidence that memory and cognition can be improved by stimulating neural rhythms at certain frequencies, Oscillo Biosciences is developing a digital therapeutic that combines music and light to restore healthy brain rhythms in patients with Alzheimer’s and MCI.
“As novel pharmaceutical interventions for Alzheimer’s Disease continue to fall short of expectations, a great deal of attention is moving to the digital device space, by both the scientific and regulatory communities. SynchronyGamma is showing promise as an effective therapeutic at the right time,” said Ed Large, Founder and Chief Science Officer of Oscillo Biosciences.
About the NIA SBIR Program
The NIA SBIR program targets early-stage research and development (R&D) and encompasses a broad range of research topics and types, including translational and secondary R&D. All applicants are expected to develop, implement and test the effectiveness of their products and services.
Small businesses and research organizations participating in NIA’s SBIR program retain intellectual property rights for their innovations. NIH’s rigorous peer-review process lends validation and visibility to early-stage companies, and the prestige associated with these awards can help attract more funding from other partners and investors.
PRESS CONTACT:
Laura Strickler
Brand Strategy and Communications Director
laura.strickler@oscillobiosciences.com
404-316-0630